View all research projects
Research project

ATTACK - Aspirin To Target Arterial Events in Chronic Kidney Disease

Project overview

Does low-dose aspirin reduce the chance of a first heart attack or stroke in patients with chronic kidney disease (CKD)?

This multicentre randomised trial will assess the effectiveness of low dose aspirin to prevent cardiovascular disease (CVD) in adult patients with chronic kidney disease(CKD). There is uncertainty about the benefits (vs CVD) and harms (bleeding) of aspirin in such patients. CKD is common and the frequency is rising and it is associated with increased risk of CVD.

Staff

Other researchers

Emeritus Professor Michael Moore

Connect with Michael

Email: mvm198@soton.ac.uk

Professor Joanne Lord

Director of SHTAC

Research interests

  • Joanne has research interests in health economic evaluation and decision modelling.
  • She has worked on a wide range of applied cost-effectiveness studies, including:
  • a review of newborn screening for inborn errors of metabolism;trials of diagnosis, patient education, structured decision-making and therapeutic interventions for arthritis and back pain;evaluations of diagnostic tests, preventive treatment and contact tracing for tuberculosis;a model of geographic allocation of resources for control of Chagas disease in Central America; andanalyses relating to the prevention and treatment of cardiovascular diseases. Her methodological contributions include an MRC funded project on whole pathway modelling for NICE clinical guidelines and an economic perspective on test evaluation. She has also contributed to health outcome and quality of life studies.
Connect with Joanne

Email: J.Lord@soton.ac.uk

Collaborating research institutes, centres and groups

Primary Care Research Centre

We are an internationally renowned centre of excellence known for conducting high-quality research to improve people’s lives. We inform and enhance evidence based primary health care in the UK and around the world.

Population Health Sciences

We research prevention of disease, reduction of health inequalities and optimisation of health and wellbeing for whole populations across the lifecourse, in the UK and internationally.

Research outputs

Aspirin for primary prevention of CVD in CKD: where do we stand?
Hugh G. Gallagher, Mark Lown, Ahmet Fuat & Paul Roderick, 2019, British Journal of General Practice, 69(689), 590-591
DOI: 10.3399/bjgp19X706661
Type: letterEditorial